Sam Wak­sal's ROCK2 biotech Gravi­ton hauls in $35M boost from Ena­vate

In­vestors are pour­ing more mon­ey in­to a biotech cre­at­ed by in­dus­try vet­er­an Sam Wak­sal, founder of Im­Clone Sys­tems, Kad­mon, MeiraGTx and Équili­bre Bio­phar­ma­ceu­ti­cals, and who has sold mul­ti­ple com­pa­nies to Big Phar­ma.

The lat­est bet, clin­i­cal-stage ROCK2 start­up Gravi­ton Bio­science, has land­ed an ad­di­tion­al $35 mil­lion in fund­ing, com­ing from lead in­vestor Pa­tient Square Cap­i­tal’s Ena­vate Sci­ences, Wak­sal told End­points News on Thurs­day af­ter­noon. He said the in­vest­ment gives Gravi­ton a high­er val­u­a­tion than dur­ing the biotech’s pri­or fi­nanc­ings from Cor­morant, Pon­tif­ax and oth­er undis­closed back­ers, who had pre­vi­ous­ly fund­ed the com­pa­ny with at least $30 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER